An update on the management of chronic lymphocytic leukaemia

Karen W L Yee, Susan M. O'Brien, Francis J. Giles*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Despite the lack of long-term survival data, the impressive results obtained with fludarabine- and rituximab-based therapies have altered the philosophy of the management of patients with chronic lymphocytic leukaemia (CLL). Therapy with chemoimmunotherapy appears to give higher responses with more patients achieving complete remission and some molecular remission. This may potentially translate into improved disease-free survival, and potentially a 'cure'. Treatment options for patients who develop resistance to fludarabine continue to be limited. This review summarises current chemo-, immuno-, and chemoimmunotherapeutic regimens that are being currently evaluated in patients with CLL. 2004

Original languageEnglish (US)
Pages (from-to)1535-1554
Number of pages20
JournalExpert Opinion on Pharmacotherapy
Issue number7
StatePublished - Jul 2004


  • Alemtuzumab
  • Chemotherapy
  • Chronic lymphocytic leukaemia
  • Cladribine
  • Fludarabine
  • Nucleoside analogues
  • Pentostatin
  • Rituximab

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'An update on the management of chronic lymphocytic leukaemia'. Together they form a unique fingerprint.

Cite this